Categorized: Peer-Reviewed, Urology

Clinical Applications of Novel ERG Immunohistochemistry in Prostate Cancer Diagnosis and Management

Immunohistochemical (IHC) staining for ERG is utilized as a surrogate for TMPRSS2: ERG gene fusions, a specific molecular event seen in ~50% of prostate carcinomas (PCas) and ~20% of high-grade prostatic intraepithelial neoplasia (HGPIN) intermingled with adjacent PCa demonstrating identical gene fusions.

To read the rest of this article, please contact Inform Diagnostics.